Sequential emergence of FLT3-ITD and BCR::ABL1 during disease progression in relapsed acute myeloid leukemia.

Authors

Hidetoshi Irifune, Yuichiro Semba, Yasufumi Uehara, Takanori Ohta, Yasuhiro Sugio, Koichi Akashi, Takahiro Maeda, Yuju Ohno

Published in

Annals of hematology. Volume 105. Issue 11. Jul 28, 2026. Epub Jul 28, 2026.

Abstract

Emergence of BCR::ABL1 during FMS-like tyrosine kinase 3 (FLT3) inhibitor therapy is a rare resistance mechanism in acute myeloid leukemia (AML). We report a case of relapsed AML with sequential clonal evolution after allogeneic hematopoietic stem cell transplantation (allo-HSCT). A previously healthy man in his 30s was diagnosed with AML with maturation; initial cytogenetics were normal, and both FLT3-internal tandem duplication (FLT3-ITD) and BCR::ABL1 were absent, while targeted sequencing identified an FBXW7 mutation. After induction failure, he underwent allo-HSCT. At post-transplant relapse during venetoclax plus azacitidine maintenance, FLT3-ITD and WT1 mutations newly emerged. Quizartinib induced remission, but a second relapse occurred with emergence of BCR::ABL1 while FLT3-ITD persisted. Cytogenetics showed t(9;22)(q34;q11), and FISH confirmed BCR::ABL1 fusion in 73% of bone marrow cells, with the minor transcript (p190) confirmed by quantitative PCR. Despite no ABL1 kinase domain mutations, imatinib and ponatinib failed to control the disease. These findings suggest that BCR::ABL1 emergence may represent a bypass resistance mechanism arising under quizartinib-associated selective pressure.

PMID:
42928344
Bibliographic data and abstract were imported from PubMed on 26 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.